Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MSFT Microsoft	$422.33 +0.1%	$398.18	$356.28 ▼ $555.45	$3.14T	1.1	35.44 million shs	20.22 million shs
NVDA NVIDIA	$219.47 -2.6%	$192.36	$129.16 ▼ $236.54	$5.31T	2.25	170.06 million shs	102.34 million shs
RDNT RadNet	$54.09 +3.2%	$58.22	$50.76 ▼ $85.84	$4.26B	1.43	832,862 shs	193,862 shs
RXRX Recursion Pharmaceuticals	$2.87 -2.2%	$3.33	$2.80 ▼ $7.18	$1.52B	1.05	16.52 million shs	13.30 million shs
SDGR Schrodinger	$12.05 +0.8%	$12.12	$10.94 ▼ $27.63	$890.27M	1.57	1.39 million shs	588,729 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MSFT Microsoft	0.00%	+1.67%	-0.21%	+5.13%	-7.12%
NVDA NVIDIA	0.00%	+4.75%	+11.72%	+23.23%	+66.41%
RDNT RadNet	0.00%	-9.97%	-13.25%	-24.66%	-14.31%
RXRX Recursion Pharmaceuticals	0.00%	-11.75%	-22.49%	-16.05%	-35.75%
SDGR Schrodinger	0.00%	-8.99%	-3.16%	+4.82%	-49.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MSFT Microsoft	$422.33 +0.1%	$398.18	$356.28 ▼ $555.45	$3.14T	1.1	35.44 million shs	20.22 million shs
NVDA NVIDIA	$219.47 -2.6%	$192.36	$129.16 ▼ $236.54	$5.31T	2.25	170.06 million shs	102.34 million shs
RDNT RadNet	$54.09 +3.2%	$58.22	$50.76 ▼ $85.84	$4.26B	1.43	832,862 shs	193,862 shs
RXRX Recursion Pharmaceuticals	$2.87 -2.2%	$3.33	$2.80 ▼ $7.18	$1.52B	1.05	16.52 million shs	13.30 million shs
SDGR Schrodinger	$12.05 +0.8%	$12.12	$10.94 ▼ $27.63	$890.27M	1.57	1.39 million shs	588,729 shs

A Guide To High-Short-Interest Stocks

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MSFT Microsoft	0.00%	+1.67%	-0.21%	+5.13%	-7.12%
NVDA NVIDIA	0.00%	+4.75%	+11.72%	+23.23%	+66.41%
RDNT RadNet	0.00%	-9.97%	-13.25%	-24.66%	-14.31%
RXRX Recursion Pharmaceuticals	0.00%	-11.75%	-22.49%	-16.05%	-35.75%
SDGR Schrodinger	0.00%	-8.99%	-3.16%	+4.82%	-49.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MSFT Microsoft	2.85	Moderate Buy	$560.88	32.81% Upside
NVDA NVIDIA	3.04	Buy	$278.73	27.00% Upside
RDNT RadNet	2.90	Moderate Buy	$88.14	62.96% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.10	182.72% Upside
SDGR Schrodinger	2.33	Hold	$20.25	68.05% Upside

Current Analyst Ratings Breakdown

Latest MSFT, NVDA, RXRX, RDNT, and SDGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/18/2026	NVDA NVIDIA	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$275.00 ➝ $300.00
5/18/2026	NVDA NVIDIA	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$250.00 ➝ $300.00
5/18/2026	NVDA NVIDIA	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$260.00 ➝ $285.00
5/18/2026	NVDA NVIDIA	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$300.00
5/15/2026	NVDA NVIDIA	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$235.00 ➝ $275.00
5/14/2026	NVDA NVIDIA	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$250.00 ➝ $250.00
5/14/2026	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$5.00 ➝ $5.50
5/14/2026	NVDA NVIDIA	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$245.00 ➝ $275.00
5/14/2026	NVDA NVIDIA	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$300.00 ➝ $350.00
5/14/2026	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$19.00 ➝ $17.00
5/13/2026	MSFT Microsoft	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$575.00

(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MSFT Microsoft	$281.72B	11.14	$18.31 per share	23.06	$46.21 per share	9.14
NVDA NVIDIA	$215.94B	24.62	$4.60 per share	47.70	$6.47 per share	33.92
RDNT RadNet	$2.04B	2.08	$3.33 per share	16.25	$17.58 per share	3.08
RXRX Recursion Pharmaceuticals	$65.74M	23.09	N/A	N/A	$2.14 per share	1.34
SDGR Schrodinger	$255.87M	3.48	N/A	N/A	$4.94 per share	2.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MSFT Microsoft	$101.83B	$16.80	25.16	21.89	1.52	39.34%	31.94%	18.47%	7/29/2026 (Estimated)
NVDA NVIDIA	$120.07B	$4.90	44.73	20.88	0.70	55.60%	97.37%	70.68%	5/20/2026 (Estimated)
RDNT RadNet	-$18.65M	-$0.18	N/A	48.73	N/A	-0.66%	2.77%	0.97%	N/A
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.20	N/A	N/A	N/A	-842.95%	-54.33%	-40.60%	8/4/2026 (Estimated)
SDGR Schrodinger	-$103.26M	-$1.41	N/A	N/A	N/A	-40.61%	-30.85%	-15.32%	8/5/2026 (Estimated)

Latest MSFT, NVDA, RXRX, RDNT, and SDGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2026	Q1 2027	NVDA NVIDIA	$1.76	N/A	N/A	N/A	$78.42 billion	N/A
5/11/2026	Q1 2026	RDNT RadNet	-$0.14	-$0.28	-$0.14	-$0.43	$557.93 million	$575.63 million
5/6/2026	Q1 2026	RXRX Recursion Pharmaceuticals	-$0.30	-$0.22	+$0.08	-$0.22	$15.78 million	$6.47 million
5/5/2026	Q1 2026	SDGR Schrodinger	-$0.56	-$0.81	-$0.25	-$0.81	$47.57 million	$58.59 million
4/29/2026	Q3 2026	MSFT Microsoft	$4.06	$4.27	+$0.21	$4.27	$81.44 billion	$82.89 billion
3/2/2026	Q4 2025	RDNT RadNet	$0.19	$0.23	+$0.04	-$0.01	$515.67 million	$547.71 million
2/25/2026	Q4 2026	NVDA NVIDIA	$1.54	$1.62	+$0.08	$1.76	$65.56 billion	$68.13 billion
2/25/2026	Q4 2025	RXRX Recursion Pharmaceuticals	-$0.28	-$0.21	+$0.07	-$0.21	$24.56 million	$35.54 million
2/25/2026	Q4 2025	SDGR Schrodinger	-$0.13	$0.44	+$0.57	$0.44	$83.66 million	$87.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MSFT Microsoft	$3.64	0.86%	+10.24%	21.67%	23 Years
NVDA NVIDIA	$0.04	0.02%	+14.87%	0.82%	1 Years
RDNT RadNet	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Latest MSFT, NVDA, RXRX, RDNT, and SDGR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/10/2026	MSFT Microsoft	quarterly	$0.91	0.9%	5/21/2026	5/21/2026	6/11/2026
2/25/2026	NVDA NVIDIA	quarterly	$0.01	0.02%	3/11/2026	3/11/2026	4/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MSFT Microsoft	0.08	1.28	1.27
NVDA NVIDIA	0.05	3.91	3.24
RDNT RadNet	0.79	1.17	1.17
RXRX Recursion Pharmaceuticals	0.01	5.47	5.47
SDGR Schrodinger	N/A	2.74	2.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MSFT Microsoft	71.13%
NVDA NVIDIA	65.27%
RDNT RadNet	77.90%
RXRX Recursion Pharmaceuticals	89.06%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
MSFT Microsoft	0.03%
NVDA NVIDIA	4.17%
RDNT RadNet	5.60%
RXRX Recursion Pharmaceuticals	8.43%
SDGR Schrodinger	10.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MSFT Microsoft	228,000	7.43 billion	7.43 billion	Optionable
NVDA NVIDIA	42,000	24.22 billion	23.21 billion	Optionable
RDNT RadNet	11,264	78.63 million	74.23 million	Optionable
RXRX Recursion Pharmaceuticals	400	529.91 million	485.23 million	Optionable
SDGR Schrodinger	790	73.82 million	66.37 million	Optionable

MSFT, NVDA, RXRX, RDNT, and SDGR Headlines

Recent News About These Companies

7 Healthcare AI Stocks Under $50 With Huge Upside Potential

May 18 at 7:35 AM | 247wallst.com

Schrodinger, Inc. (NASDAQ:SDGR) Given Consensus Rating of "Hold" by Analysts

May 17 at 2:57 AM | americanbankingnews.com

Schrodinger (NASDAQ:SDGR) Price Target Cut to $17.00 by Analysts at Morgan Stanley

May 15 at 3:41 AM | americanbankingnews.com

SchrÃ¶dinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 13, 2026 | seekingalpha.com

UBS Group AG Buys 489,059 Shares of Schrodinger, Inc. $SDGR

May 11, 2026 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Downgraded to Strong Sell Rating by Wall Street Zen

May 9, 2026 | marketbeat.com

Earnings Update: Schrödinger, Inc. (NASDAQ:SDGR) Just Reported And Analysts Are Trimming Their Forecasts

May 8, 2026 | finance.yahoo.com

Schrödinger (SDGR) Q1 2026 Earnings Transcript

May 6, 2026 | finance.yahoo.com

A Look At Schrödinger (NasdaqGS:SDGR) Valuation After Q1 Earnings And Hosted AI Software Push

May 6, 2026 | finance.yahoo.com

Schrödinger, Inc. 2026 Q1 - Results - Earnings Call Presentation

May 6, 2026 | seekingalpha.com

Schrodinger Q1 Earnings Call Highlights

May 5, 2026 | marketbeat.com

SchrÃ¶dinger, Inc. (SDGR) Q1 2026 Earnings Call Transcript

May 5, 2026 | seekingalpha.com

Schrödinger Earnings Call: Growth Now, Profits Later

May 5, 2026 | tipranks.com

Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates

May 5, 2026 | zacks.com

Schrodinger (NASDAQ:SDGR) Issues Earnings Results

May 5, 2026 | marketbeat.com

Schrödinger Reports First Quarter 2026 Financial Results

May 5, 2026 | businesswire.com

Here’s What the Street Thinks About Schrödinger (SDGR)

May 5, 2026 | insidermonkey.com

Schrodinger (NASDAQ:SDGR) Trading Up 5.8% - Here's Why

April 28, 2026 | marketbeat.com

Schrodinger (SDGR) Projected to Post Quarterly Earnings on Tuesday

April 28, 2026 | marketbeat.com

Schrodinger: AI Threat Is Looming Large (Rating Downgrade)

April 22, 2026 | seekingalpha.com

Schrodinger, Inc. (NASDAQ:SDGR) Given Average Recommendation of "Hold" by Brokerages

April 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MSFT, NVDA, RXRX, RDNT, and SDGR Company Descriptions

Microsoft NASDAQ:MSFT

$422.33 +0.41 (+0.10%)

As of 02:46 PM Eastern

Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.

NVIDIA NASDAQ:NVDA

$219.47 -5.85 (-2.60%)

As of 02:46 PM Eastern

NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.

RadNet NASDAQ:RDNT

$54.09 +1.70 (+3.24%)

As of 02:46 PM Eastern

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Recursion Pharmaceuticals NASDAQ:RXRX

$2.86 -0.07 (-2.22%)

As of 02:46 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Schrodinger NASDAQ:SDGR

$12.05 +0.10 (+0.84%)

As of 02:46 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MSFT, NVDA, RXRX, RDNT, and SDGR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MSFT, NVDA, RXRX, RDNT, and SDGR Earnings

Compare Dividends

Latest MSFT, NVDA, RXRX, RDNT, and SDGR Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MSFT, NVDA, RXRX, RDNT, and SDGR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MSFT, NVDA, RXRX, RDNT, and SDGR Company Descriptions

Microsoft NASDAQ:MSFT

NVIDIA NASDAQ:NVDA

RadNet NASDAQ:RDNT

Recursion Pharmaceuticals NASDAQ:RXRX

Schrodinger NASDAQ:SDGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools